Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02205398
Title Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

head and neck squamous cell carcinoma

Therapies

Capmatinib + Cetuximab

Age Groups: adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Massachusetts General Hospital Head & Neck Boston Massachusetts 02114 United States Details
Memorial Sloan Kettering MSKCC NY New York New York 10017 United States Details
University of Utah / Huntsman Cancer Institute Onc Dept Salt Lake City Utah 84103 United States Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Toronto Ontario M5G 1X6 Canada Details
Novartis Investigative Site Lyon Cedex 69373 France Details
Novartis Investigative Site Toulouse Cedex 9 31059 France Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Wuerzburg 97080 Germany Details
Novartis Investigative Site Ancona AN 60126 Italy Details
Novartis Investigative Site Milano MI 20162 Italy Details
Novartis Investigative Site Barcelona Catalunya 08003 Spain Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Hospitalet de LLobregat Catalunya 08907 Spain Details
Novartis Investigative Site Valencia Comunidad Valenciana 46010 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field